Clinical Trial Update: Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) [Phase 3]

View source ↗

Summary

CHARISMA studied whether adding clopidogrel to standard therapy reduces ischemic events in patients at high risk of atherothrombosis; the Phase 3 trial has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)

Snippet

Sponsor: Sanofi | Conditions: Arteriosclerosis | Phase 3 | Status: COMPLETED